Nuvectis Pharma (NVCT) Liabilities and Shareholders Equity (2021 - 2026)

Nuvectis Pharma has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $25.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 15.76% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.7 million (up 41.89% YoY) and the FY2025 annual result came in at $31.7 million, up 70.41% from the prior year.
• Liabilities and Shareholders Equity eased to $25.4 million in Q1 2026 per NVCT's latest filing, from $31.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $35.6 million in Q3 2025 and troughed at $14.2 million in Q2 2022.
• A 5-year average of $22.6 million and a median of $20.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 206.52% in 2022, then decreased 26.63% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $20.4 million in 2022, then declined by 5.98% to $19.2 million in 2023, then retreated by 3.01% to $18.6 million in 2024, then jumped by 70.41% to $31.7 million in 2025, then fell by 19.9% to $25.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $25.4 million, $31.7 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.